STRO

Company Overview — What Does SUTRO BIOPHARMA, INC. Do?

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. SUTRO BIOPHARMA, INC. (STRO) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO William J. Newell and employs approximately 240 people. With a market capitalization of $412M, STRO is one of the notable companies in the Healthcare sector.

SUTRO BIOPHARMA, INC. (STRO) Stock Rating — Hold (April 2026)

As of April 2026, SUTRO BIOPHARMA, INC. receives a Hold rating with a composite score of 34.5/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.STRO ranks #1,515 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, SUTRO BIOPHARMA, INC. ranks #132 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

STRO Stock Price and 52-Week Range

SUTRO BIOPHARMA, INC. (STRO) currently trades at $25.86. The stock lost $0.90 (3.4%) in the most recent trading session. The 52-week high for STRO is $25.99, which means the stock is currently trading -0.5% from its annual peak. The 52-week low is $0.52, putting the stock 4843.6% above its annual trough. Recent trading volume was 202K shares, suggesting relatively thin trading activity.

Is STRO Overvalued or Undervalued? — Valuation Analysis

SUTRO BIOPHARMA, INC. (STRO) carries a value factor score of 15/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-sales ratio is 4.29x, compared to 1.66x for the average Healthcare stock.

At current multiples, SUTRO BIOPHARMA, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

SUTRO BIOPHARMA, INC. Profitability — ROE, Margins, and Quality Score

SUTRO BIOPHARMA, INC. (STRO) earns a quality factor score of 16/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -1810.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -111.1% versus the sector average of -33.1%.

On a margin basis, SUTRO BIOPHARMA, INC. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -424.0% (sector: -66.1%). Net profit margin stands at -403.5%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -62.3% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

STRO Debt, Balance Sheet, and Financial Health

SUTRO BIOPHARMA, INC. has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 2.01x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $66M.

STRO has a beta of 2.11, meaning it is more volatile than the broader market — a $10,000 investment in STRO would be expected to move 111.4% more than the S&P 500 on any given day. The stability factor score for SUTRO BIOPHARMA, INC. is 13/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

SUTRO BIOPHARMA, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, SUTRO BIOPHARMA, INC. reported revenue of $99M and earnings per share (EPS) of $-22.49. Net income for the quarter was $-193M. Gross margin was 100.0%. Operating income came in at $-188M.

In FY 2025, SUTRO BIOPHARMA, INC. reported revenue of $102M and earnings per share (EPS) of $-22.49. Net income for the quarter was $-191M. Revenue grew 65.2% year-over-year compared to FY 2024. Operating income came in at $-158M.

In Q3 2025, SUTRO BIOPHARMA, INC. reported revenue of $10M and earnings per share (EPS) of $-0.67. Net income for the quarter was $-57M. Revenue grew 13.8% year-over-year compared to Q3 2024. Operating income came in at $-48M.

In Q2 2025, SUTRO BIOPHARMA, INC. reported revenue of $64M and earnings per share (EPS) of $-0.14. Net income for the quarter was $-11M. Revenue grew 148.0% year-over-year compared to Q2 2024. Operating income came in at $-3M.

Over the past 8 quarters, SUTRO BIOPHARMA, INC. has demonstrated a growth trajectory, with revenue expanding from $26M to $99M. Investors analyzing STRO stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

STRO Dividend Yield and Income Analysis

SUTRO BIOPHARMA, INC. (STRO) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

STRO Momentum and Technical Analysis Profile

SUTRO BIOPHARMA, INC. (STRO) has a momentum factor score of 80/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 20/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

STRO vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, SUTRO BIOPHARMA, INC. (STRO) ranks #132 out of 838 stocks based on the Blank Capital composite score. This places STRO in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing STRO against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full STRO vs S&P 500 (SPY) comparison to assess how SUTRO BIOPHARMA, INC. stacks up against the broader market across all factor dimensions.

STRO Next Earnings Date

No upcoming earnings date has been announced for SUTRO BIOPHARMA, INC. (STRO) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy STRO? — Investment Thesis Summary

SUTRO BIOPHARMA, INC. presents a balanced picture with arguments on both sides. The quality score of 16/100 flags below-average profitability. The value score of 15/100 indicates premium valuation. Price momentum is positive at 80/100, suggesting the trend favors buyers. High volatility (stability score 13/100) increases portfolio risk.

In summary, SUTRO BIOPHARMA, INC. (STRO) earns a Hold rating with a composite score of 34.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on STRO stock.

Related Resources for STRO Investors

Explore more research and tools: STRO vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare STRO head-to-head with peers: STRO vs AZN, STRO vs SLGL, STRO vs VMD.